Eagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated by Analysts at StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research report issued on Monday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Price Performance

NASDAQ EGRX opened at $1.20 on Monday. Eagle Pharmaceuticals has a 52-week low of $0.00 and a 52-week high of $6.37. The firm has a 50-day moving average price of $1.25 and a 200 day moving average price of $0.97.

Institutional Trading of Eagle Pharmaceuticals

A hedge fund recently bought a new stake in Eagle Pharmaceuticals stock. Jane Street Group LLC bought a new stake in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 25,837 shares of the specialty pharmaceutical company’s stock, valued at approximately $96,000. Jane Street Group LLC owned 0.20% of Eagle Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission. 85.36% of the stock is currently owned by institutional investors.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.